blinatumomab

{
  "id": "MLC-T-ONC-001108",
  "term": "blinatumomab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults and children aged 1 month and older with certain types of B-cell acute lymphoblastic leukemia that are CD19 positive (expresses the protein CD19). It is also being studied in the treatment of other types of cancer. Blinatumomab binds to CD19, which is found on most B cells (a type of white blood cell) and some types of leukemia cells. It also binds to a protein called CD3, which is found on T cells (another type of white blood cell). This may help the immune system kill cancer cells. Blinatumomab is a type of bispecific T-cell engager. Also called Blincyto.",
    "A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B lymphocytes."
  ],
  "synonyms": [
    "Blincyto",
    "anti-CD19/anti-CD3 recombinant bispecific monoclonal antibody MT103",
    "bispecific T-cell engager MT103",
    "anti-CD19 x anti-CD3 bispecific monoclonal antibody"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/blinatumomab/"
}